The FDA authorization of CELZ-201 represents a significant milestone for Creative Medical Technology Holdings, Inc., highlighting its innovative approach to healthcare. This development not only positions CELZ as a leader in T1D prevention but also has the potential to significantly impact the company's market position and investor perception positively. Given the groundbreaking nature of this therapy and its potential to address a critical healthcare need, it is likely to attract significant attention from investors, healthcare professionals, and patients, potentially driving up CELZ's stock price in the short term.